Novavax
Blood & Organ Banks · Maryland, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
21 Firstfield Rd, Gaithersburg, Maryland...Phone Number
(844) 668-2829Website
www.novavax.comRevenue
$596.3 MillionStock Symbol
NVAXIndustry
ZI Rank: 15
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
14
14
11
13
18
15
About Novavax
Novavax, Inc. is a biotechnology company incorporated in 1987 and headquartered in Gaithersburg, Maryland, focused on discovering, developing, and commercializing vaccines to protect against serious infectious diseases. The company's proprietary technology platform combines a recombinant protein approach, nanoparticle technology, and a patented adjuvant to enhance immune response. Novavax's pipeline spans vaccine candidates targeting infectious diseases including COVID-19, influenza, respiratory syncytial virus, malaria, shingles, and other pathogens, with ongoing exploration of its adjuvant platform in oncology. The company maintains a strategic partnership with Sanofi for COVID-19 vaccine commercialization and has established licensing and collaboration agreements with major global pharmaceutical companies. Novavax trades on the NASDAQ under the ticker symbol NVAX.Explore more
Novavax Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Novavax your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when Novavax launches new products
Funding: Get notified immidiatlly once Novavax has new funding data
Novavax, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Novavax is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Novavax
Check if Novavax has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Novavax recently announced quarterly report
Click to see if Novavax had a recent Job posting/layoffs
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 3 more new buyers
Compare Similar Companies to Novavax
Compare insights from companies similar to Novavax, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
$97.4M
201-500
Public
$237.2M
1997
CE
Celia EckertSenior Vice President, General Counsel & Corporate Secretary
Company Profile Activity
Activity Insights
Novavax is experiencing low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
Novavax is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about Novavax.
Novavax financials insights
Gather financial insights about Novavax, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Stock Offering
$94.6M
2014
Stock Offering
$94M
2015
Stock Offering
$201.3M
Grant
$89M
2016
Debt
$315M
2018
Stock Offering
$57.5M
2020
Multiple Rounds
$2.2B
2021
Grant
$147.3M
Novavax Tech Stack
A closer look at the technologies used by Novavax
See more technologies
Most Recent Scoops
Person-Based
Research & Development, Pharmaceuticals
Person-Based
Events
Earnings
Novavax has provided 2026 non-GAAP R&D and SG&A expense guidance of $310 million to $340 million, 2027 non-GAAP R&D and SG&A guidance with a midpoint of $225 million, and a refined 2028 non-GAAP R&D and SG&A target of $150 million to $200 million, representing an over 50% decrease compared to 2025, with 2026 GAAP combined R&D and SG&A guidance of $380 million to $420 million.
Earnings, Finance
Project
Novavax has prioritized its C. diff bacterial vaccine candidate for advancement into the clinic as early as 2027.
Product Development, Medical Research, Pharmaceuticals
Project
Research & Development, Bioengineering, Pharmaceuticals
Novavax News & Media
Novavax to Participate in 2026 Jefferies Global Healthcare Conference
GAITHERSBURG, Md., June 1, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will participate in the 2026 Jefferies Global Healthcare Conference. Conference Details: Fireside Chat Date: Thursday, June 4, 2026 Time: 10:30 – 11:00 a.m. Eastern Time Location: New York, NY...Why Novavax (NVAX) Stock Is Trading Up Today
Shares of vaccine biotechnology company Novavax (NASDAQ:NVAX) jumped 11.3% in the afternoon session after documents revealed that advisers to the U.S. Food and Drug Administration (FDA) will weigh updating the 2026-27 COVID-19 vaccines to target the latest circulating XFG subvariant.Novavax Stock Is Red Hot but the Smart Money Is Slamming on the Brakes
Although a better-than-expected Q1 earnings print has NVAX stock skyrocketing recently, there’s a high risk in chasing this biotech play.Novavax (NVAX) Q3 2025 Earnings Transcript
Unknown Executive: Good morning, and thank you all for joining us today to discuss our third quarter 2025 financial results and operational highlights. Each forward-looking statement contained in this presentation is subject to risks and uncertainties that could cause actual results to differ materially from those projected in such statements.
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Novavax
Sign Up For FreeTo access detailed company insights
Novavax, Inc. is a biotechnology company incorporated in 1987 and headquartered in Gaithersburg, Maryland, focused on discovering, developing, and commercializing vaccines to protect against serious infectious diseases. The company's proprietary technology platform combines a recombinant protein approach, nanoparticle technology, and a patented adj... Read More
